查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
2022-2029 年全球 HIV/HBV/HCV 檢測試劑盒市場
市場調查報告書
商品編碼
1166508

2022-2029 年全球 HIV/HBV/HCV 檢測試劑盒市場

Global HIV/HBV/HCV Test Kits Market - 2022-2029
出版日期: | 出版商: DataM Intelligence | 英文 180 Pages | 商品交期: 約2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄

市場概覽

在預測期內 (2022-2029)，HIV/HBV/HCV 檢測試劑盒的全球市場規模預計將以 6.8% 的複合年增長率增長。

HIV/HBV/HCV檢測是定性檢測和檢測人血清、血漿和血液中的乙型肝炎表面抗原（HBsAg）和HIV-1、HIV-2、梅毒螺旋體（Tp）和HCV抗體。全血 HIV/HBV/HCV 檢測用於定性檢測和區分人血清、血漿和全血中的 HV-2、Tp 和 HCV 抗體。

市場動態

HIV/HBV/HCV 快速檢測試劑盒的技術創新有望推動市場增長。

在合併感染率很高的撒哈拉以南非洲地區，HIV、HBV 和 HCV 感染的負擔繼續高得不成比例。 用於 HIV、HBV 和 HCV 血清學檢測的高分析性能多重快速診斷方法有可能加強篩查級聯並導致更具成本效益的護理聯繫。 這種檢測方法對難以接近的高危人群特別有用，並可能增加自我檢測對公共衛生的影響。 例如，原型指尖全血三重 HIV/HCV/HBsAg 自檢可以提供一種快速、廉價、無需工具且易於使用的方法來識別 HIV、HBV 和 HCV 感染。 特別是，它可能適用於改進撒哈拉以南非洲地區三種密切相關的地方病的篩查。 這些選擇將增加篩查工作，降低因未確診的 HIV、HBV 或 HCV 感染引起的疾病的未來成本，治療這些感染，並支持根除 HCV 感染的努力。這是有可能的。 因此，預計上述因素將在預測期內推動市場。

人們對慢性乙型和丙型肝炎缺乏了解和認識預計會阻礙市場增長。

根據國家醫學圖書館的說法，醫療保健提供者、社會服務提供者和公眾並不知道乙型和丙型肝炎的傳播。 缺乏對美國慢性病毒性肝炎流行的認識以及慢性乙型和丙型肝炎篩查和醫療管理的適當方法和目標可能導致持續傳播，失去疫苗接種等預防機會，這很可能導致導致早期診斷和錯失醫療機會，以及感染者健康狀況的惡化。 因此，預計上述因素將在預測期內阻礙市場。

行業分析

HIV/HBV/HCV 測試套件市場根據各種行業因素（包括供應鏈分析、價格分析等）對市場進行深入分析。

COVID-19 影響分析

COVID-19 大流行對市場產生了一定程度的影響。 大流行擾亂了醫療保健系統，使提供基本臨床護理、HIV/HBV/HCV 檢測和治療變得更加困難。 因此，在大流行期間未被診斷出患有 HIV、HBV 和 HCV 的人隨後可能會被發現患有更晚期的疾病，從而導致發病率和死亡率增加。 根據世界衛生組織 (WHO) 的數據，2020 年有 10 個國家的乙肝檢測中斷，6 個國家的丙肝治療中斷，5 個國家的計劃生育中斷。 同樣在 2020 年，作為 COVID-19 自身的大流行緩解措施的一部分，CDC 發布了關於推遲常規臨床就診和延遲非必要工作的指南。 該建議可讓患者避免不必要的面對面諮詢，並通過遠程醫療、患者門戶、電話、電子郵件等方式與醫療保健提供者進行溝通。 因此，COVID-19 大流行正在影響市場。 然而，這種情況預計將在預測期內逐漸改善。

內容

第一章研究方法與範圍

  • 調查方法
  • 調查目的和範圍

第 2 章市場定義和概述

第 3 章執行摘要

第四章市場動態

  • 市場影響因素
    • 司機
      • HIV/HBV/HCV 快速檢測試劑盒的技術創新有望推動市場增長。
    • 約束因素
      • 人們對慢性乙型肝炎和丙型肝炎缺乏了解和認識預計會阻礙市場增長。
    • 機會
    • 影響分析

第五章行業分析

  • 供應鏈分析
  • 定價分析

第 6 章 COVID-19 分析

  • COVID-19 市場分析
    • COVID-19 之前的市場情景
    • COVID-19 的當前市場情景
    • COVID-19 後或未來情景
  • COVID-19 期間的價格動態
  • 供需範圍
  • 大流行期間與市場相關的政府舉措
  • 製造商的戰略舉措
  • 總結

第 7 章按測試類型

  • 快速測試套件
  • 基於化驗的測試套件

第 8 章按樣本類型

  • 唾液
  • 血液
  • 尿液

第 9 章最終用戶

  • 醫院
  • 診斷實驗室
  • 醫務室
  • 政府機構、非政府組織
  • 其他

第10章按地區

  • 北美
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 英國
    • 法國
    • 意大利
    • 西班牙
    • 其他歐洲
  • 南美洲
    • 巴西
    • 阿根廷
    • 其他南美洲
  • 亞太地區
    • 中國
    • 印度
    • 日本
    • 澳大利亞
    • 其他亞太地區
  • 中東和非洲

第11章競爭格局

  • 主要發展和戰略
  • 公司股票分析
  • 值得關注的主要公司名單

第12章公司簡介

  • F. Hoffmann-La Roche Ltd
    • 公司簡介
    • 產品組合和內容
    • 主要亮點
    • 財務摘要
  • Bio-Rad Laboratories Inc.
  • Abbott Laboratories
  • Meridian Bioscience, Inc.
  • Biopanda Reagents Ltd
  • Nanjing Synthgene Medical Technology Co., Ltd.
  • AccuBioTech Co., Ltd.
  • BioMerieux SA
  • QIAGEN
  • Hologic Inc
  • Creative Diagnostics

第13章 HIV/HBV/HCV 檢測試劑盒的全球市場-DataM

簡介目錄
Product Code: DMCD1250

Market Overview

The global HIV/HBV/HCV test kits market size was valued US$ YY million in 2021 and is expected to reach US$ XX million by 2029, growing at a CAGR of 6.8 % during the forecast period (2022-2029).

HIV/HBV/HCV test is a test of qualitative detection and differentiation of hepatitis B surface antigen (HBsAg) and antibodies to HIV-1, HIV-2, Treponema pallidum (Tp), and HCV in human serum, plasma, or whole blood.

Market Dynamics

Innovations in the HIV/HBV/HCV rapid test kits is expected to drive market growth.

In sub-Saharan Africa, where co-infection rates are high, the burden of HIV, HBV, and HCV infections continues to be disproportionately high. High analytical performance multiplex fast diagnostic procedures for HIV, HBV, and HCV serological testing may enhance the cascade of screening and result in more cost-effective linkage to care. Such a testing approach may be especially helpful for high-risk populations challenging to reach and may also boost the impact of self-testing on public health. For instance, The prototype finger-stick whole-blood Triplex HIV/HCV/HBsAg self-test may offer a quick, affordable, tool-free, and user-friendly method for identifying HIV, HBV, and HCV infections. It might be especially appropriate for improving the screening of three endemic viral illnesses closely related in sub-Saharan Africa. These options could increase screening efforts, lowering the future cost of diseases caused by undiagnosed HIV, HBV, or HCV infections and assisting with efforts to treat these infections and potentially eradicate HCV infection. Thus, from the above factors, the market is expected to drive in the forecast period.

Lack of knowledge and awareness about chronic hepatitis B and hepatitis C among people is expected to hamper the market growth.

According to the National Library of Medicine, healthcare providers, social-service providers, and the general public are unaware of hepatitis b&c infections. Lack of awareness about the prevalence of chronic viral hepatitis in the U.S., as well as the appropriate methods and target populations for screening and medical management of chronic hepatitis B and hepatitis C, most likely contributes to ongoing transmission; missed opportunities for prevention, including vaccination; missed opportunities for early diagnosis and medical care; and poor health outcomes in infected people. Thus, from the above-mentioned factors, the market is expected to get hampered in the forecast period.

Industry Analysis

The HIV/HBV/HCV test kits market provides in-depth analysis of the market based on various industry factors such as supply chain analysis, pricing analysis etc.

COVID-19 Impact Analysis

The COVID-19 pandemic has moderately impacted the market. The pandemic has disrupted healthcare systems, making it more difficult to provide basic clinical care, HIV/HBV/HCV testing, and treatment. As a result, increased morbidity and mortality rates may result from those who had undiagnosed HIV, HBV, and HCV during the pandemic subsequently being found to have the disease in more advanced stages. Besides, according to the World Health Organisation, in 2020, 10 countries reported disruption in Hepatitis B testing, 6 in Hepatitis C Treatment initiation, and 5 in Family Planning. In addition, as part of the original COVID-19 pandemic mitigation initiatives, in 2020, the CDC published guidelines on deferring routine clinical visits and delaying non-essential operations. With this advice, patients avoid making unnecessary in-person visits and communicate with their healthcare practitioner via telemedicine, patient portals, phone, and email. Thus, the COVID-19 pandemic has affected the market. However, the situation is expected to improve gradually in the forecast period.

Segment Analysis

Assay Based Test Kits segment is expected to hold the largest market share in HIV/HBV/HCV test kits market

The assay-based test kits segment accounted for the largest market share in 2021. The segment benefits because these are the first line of patient tests. Moreover, healthcare professionals and patients in most developing regions rely on assay-based testing results. For instance, The HCV Ag assay has the advantages of being an immunoassay, not requiring the same time-consuming and costly sample processing as molecular diagnostics, and confirming current infection. Moreover, there have been innovations in assay-based test kits. For instance, One point-of-care test that uses the GeneXpert System is the Xpert HCV Viral Load Fingerstick Test from Cepheid. The finger-stick whole blood capillaries is examined for HCV RNA as part of this point-of-care test (or assay). This type of HCV testing involves taking capillary blood from the patient through a finger prick into a collection device called a Minivette, which is then processed in a GeneXpert device at or near the point-of-care testing location.

In addition, most patients with acquired immunodeficiency syndrome (AIDS) and AIDS-related complex (ARC), as well as many asymptomatic people in high-risk groups, have been found to have antibodies to the human immunodeficiency virus (HIV). The existence of these HIV antibodies is frequently checked in human blood and plasma samples using enzyme-linked immunosorbent assays (ELISA). For instance, INNO-LIA HIV I/II Score is a Line Immuno Assay (LIA) that establishes the existence of antibodies against HIV-1, including group O and HIV-2 in human blood or plasma. The HIV I/II Score from INNO-LIA distinguishes between HIV-1 and HIV-2 infections. It is meant to be used in addition to an anti-HIV screening process on reactive specimens. Therefore, it has increased the demand for assay-based test kits. Thus, from the above factors, the market segment is expected to hold the largest market share in the forecast period.

Geographical Analysis

Middle East and Africa region holds the largest market share in the global HIV/HBV/HCV test kits market

In 2021, the Middle East and Africa accounted for the highest revenue share. The increasing prevalence of HIV, innovations in the HIV/HBV/HCV test kits, advancing guidelines for self-testing and well-established infrastructure in the region are some factors the market is expected to boost in the forecast period. For instance, according to the UNAIDS, in 2020, HIV prevalence in Eswatini was 26.8 %. HIV prevalence in Eswatini increased from 22.9 % in 2001 to 26.8 % in 2020, growing at an average annual rate of 0.84%. Moreover, new WHO guidelines strongly advise offering self-testing for the hepatitis C virus (HCV) as an alternate method to HCV testing facilities. On the occasion of the International AIDS Society Conference in 2021, WHO issued the updated guidelines-it is the first for HCV self-testing. The new guidelines highlight important factors that should be taken into account by national programs, service providers, and implementers of HCV testing. These factors for HCV self-testing include developing suitable and context-specific messages, service delivery models, and support tools through community engagement; creating effective pathways for people who self-test to obtain confirmatory testing and treatment or prevention services; educating providers; creating a supportive and enabling policy environment; and using quality-assured products. Besides, WHO has also developed technical specifications for prequalifying HCV self-testing products to ensure quality. Therefore, it has increased the demand for HIV/HBV/HCV test kits. Thus, from the above factors, the Middle East and Africa region is expected to hold the largest market share in the forecast period.

Competitive Landscape

Major key players in the HIV/HBV/HCV test kits market are F. Hoffmann-La Roche Ltd; Bio-Rad Laboratories Inc.; Abbott Laboratories; Meridian Bioscience, Inc.; Biopanda Reagents Ltd; Nanjing Synthgene Medical Technology Co., Ltd.; AccuBioTech Co., Ltd.; BioMerieux SA; QIAGEN; Hologic Inc; and Creative Diagnostics.

F. Hoffmann-La Roche Ltd:

Overview:

Hoffmann-La Roche Ltd is a leader in research-focused healthcare with combined strengths in pharmaceuticals and diagnostics. It is one of the largest biotech companies, with truly differentiated medicines in oncology, immunology, infectious diseases, ophthalmology, and neuroscience. It is a global leader in in-vitro and tissue-based cancer diagnostics and a frontrunner in diabetes management. Its personalized healthcare strategy aims to provide medicines and diagnostics that enable tangible improvements in patients' health, quality of life and survival. Moreover, Roche Molecular, one of four customer-focused areas of Roche Diagnostics Solutions, develops, manufactures and supplies a wide array of innovative molecular diagnostic products, tests, platforms and technologies used to identify and quantify DNA and RNA from different organisms.

Product Portfolio:

cobas MPX: The cobas MPX Test is a multi-dye, real-time PCR multiplex test for human immunodeficiency virus (HIV), hepatitis C virus (HCV) and hepatitis B virus (HBV) for use on the cobas 6800/8800 Systems. The single assay allows for simultaneous detection of three targets, improving efficiency and accuracy.

The global HIV/HBV/HCV test kits market report would provide an access to an approx. 45+market data table, 40+figures and 180pages.

Table of Contents

1. Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Market Definition and Overview

3. Executive Summary

4. Market Dynamics

  • 4.1. Market Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. Innovations in the HIV/HBV/HCV rapid test kits are expected to drive market growth.
    • 4.1.2. Restraints:
      • 4.1.2.1. Lack of knowledge and awareness about chronic hepatitis B and hepatitis C among people is expected to hamper the market growth.
    • 4.1.3. Opportunity
    • 4.1.4. Impact Analysis

5. Industry Analysis

  • 5.1. Supply Chain Analysis
  • 5.2. Pricing Analysis

6. COVID-19 Analysis

  • 6.1. Analysis of Covid-19 on the Market
    • 6.1.1. Before COVID-19 Market Scenario
    • 6.1.2. Present COVID-19 Market Scenario
    • 6.1.3. After COVID-19 or Future Scenario
  • 6.2. Pricing Dynamics Amid Covid-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During Pandemic
  • 6.5. Manufacturers Strategic Initiatives
  • 6.6. Conclusion

7. By Test Type

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Test Type
    • 7.1.2. Market Attractiveness Index, By Test Type Segment
  • 7.2. Rapid Test Kits*
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 7.3. Assay Based Test Kits

8. By Sample Type

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Sample Type
    • 8.1.2. Market Attractiveness Index, By Sample Type Segment
  • 8.2. Saliva*
    • 8.2.1. Introduction
    • 8.2.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 8.3. Blood
  • 8.4. Urine

9. By End user

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End user
    • 9.1.2. Market Attractiveness Index, By End user Segment
  • 9.2. Hospitals*
    • 9.2.1. Introduction
    • 9.2.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 9.3. Diagnostic Laboratories
  • 9.4. Clinics
  • 9.5. Government Organizations and NGO's
  • 9.6. Others

10. By Region

  • 10.1. Introduction
    • 10.1.1. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029, By Region
    • 10.1.2. Market Attractiveness Index, By Region
  • 10.2. North America
    • 10.2.1. Introduction
    • 10.2.2. Key Region-Specific Dynamics
    • 10.2.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Test Type
    • 10.2.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Sample Type
    • 10.2.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End user
    • 10.2.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.2.6.1. U.S.
      • 10.2.6.2. Canada
      • 10.2.6.3. Mexico
  • 10.3. Europe
    • 10.3.1. Introduction
    • 10.3.2. Key Region-Specific Dynamics
    • 10.3.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Test Type
    • 10.3.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Sample Type
    • 10.3.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End user
    • 10.3.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.3.6.1. Germany
      • 10.3.6.2. U.K.
      • 10.3.6.3. France
      • 10.3.6.4. Italy
      • 10.3.6.5. Spain
      • 10.3.6.6. Rest of Europe
  • 10.4. South America
    • 10.4.1. Introduction
    • 10.4.2. Key Region-Specific Dynamics
    • 10.4.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Test Type
    • 10.4.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Sample Type
    • 10.4.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End user
    • 10.4.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.4.6.1. Brazil
      • 10.4.6.2. Argentina
      • 10.4.6.3. Rest of South America
  • 10.5. Asia Pacific
    • 10.5.1. Introduction
    • 10.5.2. Key Region-Specific Dynamics
    • 10.5.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Test Type
    • 10.5.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Sample Type
    • 10.5.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End user
    • 10.5.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.5.6.1. China
      • 10.5.6.2. India
      • 10.5.6.3. Japan
      • 10.5.6.4. Australia
      • 10.5.6.5. Rest of Asia Pacific
  • 10.6. Middle East and Africa
    • 10.6.1. Introduction
    • 10.6.2. Key Region-Specific Dynamics
    • 10.6.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Test Type
    • 10.6.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Sample Type
    • 10.6.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End user

11. Competitive Landscape

  • 11.1. Key Developments and Strategies
  • 11.2. Company Share Analysis
  • 11.3. List of Key Companies to Watch

12. Company Profiles

  • 12.1. F. Hoffmann-La Roche Ltd*
    • 12.1.1. Company Overview
    • 12.1.2. Product Portfolio and Description
    • 12.1.3. Key Highlights
    • 12.1.4. Financial Overview
  • 12.2. Bio-Rad Laboratories Inc.
  • 12.3. Abbott Laboratories
  • 12.4. Meridian Bioscience, Inc.
  • 12.5. Biopanda Reagents Ltd
  • 12.6. Nanjing Synthgene Medical Technology Co., Ltd.
  • 12.7. AccuBioTech Co., Ltd.
  • 12.8. BioMerieux SA
  • 12.9. QIAGEN
  • 12.10. Hologic Inc
  • 12.11. Creative Diagnostics

LIST NOT EXHAUSTIVE

13. Global HIV/HBV/HCV Test Kits Market - DataM

  • 13.1. Appendix
  • 13.2. About Us and Applications
  • 13.3. Contact Us